KR102413412B1 - 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 - Google Patents

암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 Download PDF

Info

Publication number
KR102413412B1
KR102413412B1 KR1020187028391A KR20187028391A KR102413412B1 KR 102413412 B1 KR102413412 B1 KR 102413412B1 KR 1020187028391 A KR1020187028391 A KR 1020187028391A KR 20187028391 A KR20187028391 A KR 20187028391A KR 102413412 B1 KR102413412 B1 KR 102413412B1
Authority
KR
South Korea
Prior art keywords
grp78
cells
hours
administration
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187028391A
Other languages
English (en)
Korean (ko)
Other versions
KR20180130509A (ko
Inventor
수잔 베이크웰
죠티 세투라만
Original Assignee
볼드 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 볼드 테라퓨틱스 인코포레이티드 filed Critical 볼드 테라퓨틱스 인코포레이티드
Priority to KR1020227017618A priority Critical patent/KR20220075450A/ko
Publication of KR20180130509A publication Critical patent/KR20180130509A/ko
Application granted granted Critical
Publication of KR102413412B1 publication Critical patent/KR102413412B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020187028391A 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 Active KR102413412B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227017618A KR20220075450A (ko) 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301786P 2016-03-01 2016-03-01
US62/301,786 2016-03-01
PCT/US2017/020209 WO2017151775A1 (en) 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017618A Division KR20220075450A (ko) 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도

Publications (2)

Publication Number Publication Date
KR20180130509A KR20180130509A (ko) 2018-12-07
KR102413412B1 true KR102413412B1 (ko) 2022-06-28

Family

ID=59744351

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187028391A Active KR102413412B1 (ko) 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도
KR1020227017618A Ceased KR20220075450A (ko) 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227017618A Ceased KR20220075450A (ko) 2016-03-01 2017-03-01 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도

Country Status (8)

Country Link
US (4) US10821095B2 (cg-RX-API-DMAC10.html)
EP (1) EP3423055B1 (cg-RX-API-DMAC10.html)
JP (3) JP6997919B2 (cg-RX-API-DMAC10.html)
KR (2) KR102413412B1 (cg-RX-API-DMAC10.html)
CN (1) CN109195600A (cg-RX-API-DMAC10.html)
AU (1) AU2017227705A1 (cg-RX-API-DMAC10.html)
IL (2) IL299223A (cg-RX-API-DMAC10.html)
WO (2) WO2017151762A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299223A (en) * 2016-03-01 2023-02-01 Intezyne Tech Use of trans-[tetrachlorobis(1H-indazole)rotonate(III)] for cancer treatment
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
US11730750B2 (en) 2020-02-17 2023-08-22 University Of Kentucky Research Foundation Drugs for GRP78 cell surface translocation and Par-4 secretion
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
KR20240091105A (ko) * 2021-10-28 2024-06-21 볼드 테라퓨틱스 인코포레이티드 프로테아좀 억제제 내성을 개선시키기 위한 나트륨 트랜스-[테트라클로리도비스(1h-인다졸)루테네이트(iii)]의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531065A (ja) 2010-07-18 2013-08-01 ニッキ ファーマ インク． ルテニウム錯体を用いる併用療法
US10821095B2 (en) 2016-03-01 2020-11-03 Bold Therapeutics, Inc. Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2441262T3 (es) 2007-06-11 2014-02-03 Niiki Pharma Inc. Método de fabricación de un complejo de rutenio
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013531065A (ja) 2010-07-18 2013-08-01 ニッキ ファーマ インク． ルテニウム錯体を用いる併用療法
KR101783190B1 (ko) 2010-07-18 2017-09-29 니키 파머 액퀴지션 코포레이션 2 루테늄 착체를 사용하는 병용 치료요법
US10821095B2 (en) 2016-03-01 2020-11-03 Bold Therapeutics, Inc. Use of trans-[tetrachlorobis(1H-indazole)ruthenate(III)] for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma, Mol Cancer Ther.,15(5), 1043-52(2016.03.03.)
NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer, BMC Pharmacology and Toxicology, 13, A82(2012.09.17.)
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application, Chem. Sci., 2014, 5, 2925
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo, Eur J Cancer. 2013 Oct; 49(15): 3366-3375
Trondl, NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application, Chem. Sci., 2925,(2014.05.) 1부.*

Also Published As

Publication number Publication date
EP3423055B1 (en) 2026-07-08
US10821095B2 (en) 2020-11-03
AU2017227705A1 (en) 2018-10-18
EP3423055A1 (en) 2019-01-09
US20240091196A1 (en) 2024-03-21
IL299223A (en) 2023-02-01
JP7513574B2 (ja) 2024-07-09
WO2017151762A1 (en) 2017-09-08
IL261384B1 (en) 2023-01-01
KR20180130509A (ko) 2018-12-07
JP6997919B2 (ja) 2022-01-18
US20210085647A1 (en) 2021-03-25
AU2017227705A9 (en) 2018-12-20
WO2017151775A1 (en) 2017-09-08
IL261384B2 (en) 2023-05-01
EP3423055A4 (en) 2019-10-16
JP2019507166A (ja) 2019-03-14
US20190038601A1 (en) 2019-02-07
US20250387370A1 (en) 2025-12-25
KR20220075450A (ko) 2022-06-08
CN109195600A (zh) 2019-01-11
JP2021167360A (ja) 2021-10-21
WO2017151775A9 (en) 2018-09-13
JP2023024618A (ja) 2023-02-16
IL261384A (en) 2018-10-31
US11633380B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
JP7513574B2 (ja) がんの処置のためのトランス－［テトラクロロビス（１ｈ－インダゾール）ルテネート（ｉｉｉ）］の使用
Osada et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations
Cao et al. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells
Li et al. Metformin sensitizes EGFR-TKI–resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal
Zhao et al. Stromal modulation reverses primary resistance to immune checkpoint blockade in pancreatic cancer
Li et al. Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma
Mabuchi et al. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model
Duan et al. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo
Fu et al. Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma
Wang et al. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer
Zhuang et al. Solasodine inhibits human colorectal cancer cells through suppression of the AKT/glycogen synthase kinase‐3β/β‐catenin pathway
Oh et al. Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Lee et al. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer
Huang et al. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia
Shin et al. Mithramycin A inhibits myeloid cell leukemia-1 to induce apoptosis in oral squamous cell carcinomas and tumor xenograft through activation of Bax and oligomerization
Cavalloni et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
Chen et al. Synergetic impact of combined navoximod with cisplatin mitigates chemo-immune resistance via blockading IDO1+ CAFs-secreted Kyn/AhR/IL-6 and pol ζ-prevented CIN in human oral squamous cell carcinoma
Xia et al. Cisatracurium regulates the CXCR4/let-7a-5p axis to inhibit colorectal cancer progression by suppressing TGF-β/SMAD2/3 signalling
CN114126652A (zh) 抗肿瘤剂和配合剂
Zhang et al. Methionine enkephalin suppresses lung cancer metastasis by regulating the polarization of tumor-associated macrophages and the distribution of myeloid-derived suppressor cells in the tumor microenvironment and inhibiting epithelial-mesenchymal transition
Waddell et al. VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis
Chen et al. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib
Singhal et al. Novel compound 1, 3-bis (3, 5-dichlorophenyl) urea inhibits lung cancer progression
Maloney et al. Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane
Dong Investigating Novel Inhibitors of Epithelial–Mesenchymal Transition (EMT) and Cancer Stem Cells (CSCs) in Pancreatic Cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5